New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
07:56 EDTAZN, T, LAZ, PFE, BAC, DTV, JPMLazard shares rise after AT&T mega-deal struck, WSJ says
Shares of Lazard (LAZ) rose yesterday after AT&T (T), which Lazard was the advisor for, announced its deal to acquire DirecTV (DTV), reported The Wall Street Journal. In contrast, JPMorgan (JPM), Bank of America (BAC) and Guggenheim Partners look set to be disappointed and lose out on potential fees as Pfizer's (PFE) bid for AstraZeneca (AZN) appears destined to fail, the report noted. The Journal added that the total value of agreed-upon U.S. deals is up 87% from last year to $585B year-to-date. Reference Link
News For LAZ;JPM;BAC;T;DTV;PFE;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
January 14, 2015
07:37 EDTAZNJPMorgan to hold a conference
Subscribe for More Information
07:34 EDTBACNew rules prompt BofA to sever ties with 150 hedge funds, Bloomberg reports
Subscribe for More Information
07:20 EDTJPMJPMorgan reports Q4 results include $990M after-tax legal expense
Subscribe for More Information
07:10 EDTJPMJPMorgan Q4-end book value per share $57.07
Subscribe for More Information
07:06 EDTJPMJPMorgan reports Q4 core loans up 8% compared with the prior year
Subscribe for More Information
07:05 EDTJPMJPMorgan reports Q4 mortgage originations improved sequentially
CEO Jamie Dimon said: “Our businesses continue to demonstrate strong momentum and expense discipline. Consumer & Community Banking delivered impressive growth in deposits and investment assets in the fourth quarter and throughout 2014, while outperforming its expense reduction target for the year. Mortgage originations improved sequentially in the fourth quarter, despite a seasonally slow quarter. Our Card business delivered double-digit sales volume growth, outpacing the industry for the 27th consecutive quarter. Auto had a good quarter and the pipeline remains strong. The Corporate & Investment Bank saw strong performance in fees, maintaining its #1 position in Global IB fees in 2014 with particular strength in Europe, although Markets remained somewhat challenged. Commercial Banking grew period-end loans 8% versus the prior year and Commercial Banking clients generated record investment banking revenues for the quarter and the year. Lastly, Asset Management had over $80B of net long-term inflows for the second consecutive year and overall AUM grew 9% this quarter compared to the prior year.”
07:03 EDTJPMJPMorgan reports Q4 provision for credit losses $840M
Subscribe for More Information
07:03 EDTAZNAstraZeneca says Pegasus-TIMI 54 study met primary efficacy endpoint
AstraZeneca announced that the PEGASUS-TIMI 54 study, a large scale outcomes trial involving over 21,000 patients, successfully met its primary efficacy endpoint. The study assessed BRILINTA tablets at either 60mg twice daily or 90mg twice daily plus low-dose aspirin for the secondary prevention of atherothrombotic events in patients who had experienced a heart attack one to three years prior to study start. The primary efficacy endpoint was a composite of cardiovascular death, myocardial infarction or stroke. Preliminary analysis did not reveal any unexpected safety issues. Full evaluation of the data is ongoing. The PEGASUS-TIMI 54 study investigated two different doses of ticagrelor on a background of low dose aspirin versus placebo plus low dose aspirin, in patients aged 50 and older with a history of heart attack and one additional CV risk factor. The study was designed to better understand the management of patients more than 12 months after their heart attack, who remain at high risk for major thrombotic events. Complete results from the PEGASUS-TIMI 54 study will be submitted to a scientific meeting in 2015 and pending further analysis, AstraZeneca plans to file this data with regulatory health authorities. The PEGASUS-TIMI 54 study is part of AstraZeneca’s PARTHENON program. The PLATO study, involving over 18,000 ACS patients, was the first study in the program and is the basis on which ticagrelor has been approved in over 100 countries and included in 12 major ACS treatment guidelines globally. Further ongoing PARTHENON studies are investigating ticagrelor for the prevention of cardiovascular events in patients with peripheral arterial disease, ischaemic stroke or transient ischaemic attack, and in patients with diabetes and coronary atherosclerosis. BRILINTA is not approved for secondary prevention of atherothrombotic events in patients with a history of heart attack beyond one year or for the prevention of cardiovascular events in patients with PAD, stroke, diabetes or atherosclerosis.
07:03 EDTAZNAstraZeneca says Pegasus-TIMI 54 study met primary efficacy endpoint
07:00 EDTJPMJPMorgan reports Q4 EPS $1.19, consensus $1.31
Subscribe for More Information
06:57 EDTBACBarclays appoints Jonathan Moulds as Group COO
Subscribe for More Information
06:45 EDTJPMJPMorgan downgraded to Underweight from Neutral at HSBC
Subscribe for More Information
January 13, 2015
15:21 EDTJPMNotable companies reporting before tomorrow's open
Subscribe for More Information
15:12 EDTBAC, JPMU.S. Supreme Court decision gives homeowners leeway to rescind mortgage loans
In an unanimous ruling, the U.S. Supreme Court ruled on Jesinoski vs. Countrywide Home Loans that homeowners are allowed to rescind home mortgages within the three years allotted under the Truth in Lending Act of 1968 by providing written notice to his/her lender. The court ruled that the borrowers were not required to file suit against the lender, which the respondents, Countrywide, claimed. The notice of rescission was sufficient to clear the homeowners of any obligation to the loan, provided they do it within the allotted time. Countrywide Home Loans is a subsidiary of Bank of America (BAC). Other publicly traded companies in the banking space include Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
15:03 EDTJPMJPMorgan technical notes ahead of results
Subscribe for More Information
14:20 EDTJPMJPMorgan January 58.5 straddle priced for 2.9% movement into Q4
14:02 EDTJPMEarnings Preview: JPMorgan to report results after upbeat analyst notes
Subscribe for More Information
11:20 EDTBACBank of America January volatility elevated into Q4 and outlook
Subscribe for More Information
07:44 EDTJPM, BACNationstar, non-bank lenders could get boost from refis, WSJ says
As a decline in interest rates and a reduction in federal loan fees boosts refinancing activity, smaller banks and non-bank lenders, such as Quicken Loans, loanDepot, and Nationstar Mortgage (NSM), may be in a better position than large banks to benefit, said The Wall Street Journal. Publicly traded large U.S. banks include Bank of America (BAC), Citi (C), JPMorgan (JPM), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
07:05 EDTJPMJPMorgan volatility increases into Q4 and outlook
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use